Parainfluenza Clinical Trial
Official title:
An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with
parainfluenza infection.
All subjects will have additional PK and Immunogenicity blood samples collected.
The study will investigate the safety, tolerability, clinical and virologic effect of DAS1814
for the treatment of PIV infections in up to 60 immunocompromised patients with no other
treatment options.
Eligible immunocompromised patients positively diagnosed with PIV infection will receive
DAS181 by DPI or Nebulized formulation.
DPI: 10 mg DAS181 will be administered for seven (7) consecutive days for up to a total
cumulative dose of 70mg.
Nebulized: DAS181 F02 formulation in solution will be administered for seven (7) consecutive
days for up to a total cumulative dose of 28.9 mg.
Assessment of viral shedding and viral resistance testing will be performed on collected
viral load samples. Blood samples will be obtained to evaluate safety at each scheduled
visit.
Routine safety monitoring (including Adverse Event (AE) reporting, clinical laboratory tests,
vital signs, electrocardiogram (ECG) and )2 levels) will be conducted in all subjects. A
final safety assessment will occur at Day 28 (+/- 2 days) after enrollment/first dose of
study drug. Survival, diary cards, and quality of life will be collected at Day 60 and 90. PK
will be collected at each visit on all subjects from baseline/visit 2 to visit 11/Day 28.
Immunogenicity samples will be collected at selected time points in all subjects.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
| Suspended |
NCT00186927 -
A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers
|
Phase 1 | |
| Recruiting |
NCT03808922 -
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
|
Phase 3 | |
| Completed |
NCT01644877 -
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
|
Phase 2 | |
| Completed |
NCT00641017 -
Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine
|
Phase 1 |